Welcome to our dedicated page for Astrana Health SEC filings (Ticker: ASTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Astrana Health, Inc. (NASDAQ: ASTH), a physician-centric, AI-powered and technology-enabled healthcare company focused on value-based care and population health management. Through these filings, investors can review how Astrana reports its financial condition, segment performance, acquisitions, and other material events.
Astrana’s periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, describe the company’s three reportable segments—Care Partners, Care Delivery, and Care Enablement—and present detailed revenue and expense information. These filings also discuss topics such as medical liabilities, long-term debt, noncontrolling interests, and the structure of consolidated entities and variable interest entities.
Current reports on Form 8-K and amendments on Form 8-K/A document significant developments, including quarterly earnings announcements, updated investor presentations, and the completion and accounting treatment of acquisitions. For example, Astrana has filed 8-Ks and 8-K/As related to the closing of the Prospect Health acquisition, associated credit agreements, and the inclusion of audited financial statements and unaudited pro forma financial information for the acquired business.
Investors interested in transaction details, guidance updates, and capital structure changes can use these filings to understand how Astrana finances acquisitions, manages leverage, and integrates new entities into its operations. Regulation FD disclosures and furnished exhibits, such as earnings presentations and investor decks, offer additional context on the company’s strategy and performance.
Stock Titan’s tools surface Astrana Health’s latest SEC filings in near real time and apply AI-powered summaries to help explain the key points in lengthy documents. Users can quickly scan 10-K and 10-Q highlights, review 8-K event descriptions, and identify exhibits related to acquisitions, credit facilities, and pro forma financials. Form 4 insider transaction filings, when available, can also be accessed to see reported trading activity by company insiders.
By using this SEC filings page, readers gain a structured view of Astrana Health’s regulatory disclosures, from core financial statements to acquisition-related information and investor communications, supported by AI-generated insights that make complex filings easier to interpret.
Astrana Health Chief Medical Officer Dinesh M. Kumar reported routine equity compensation activity. On April 1, 2026, he received 35,300 shares of common stock at no cost upon vesting of performance-based restricted stock units after performance exceeded target levels. On the same date, 57,980 shares were surrendered at $24.51 per share to cover tax withholding obligations tied to vesting restricted stock and restricted stock units, rather than being sold on the open market. After these transactions, he directly held 177,655 shares, including time-based restricted stock and restricted stock units scheduled to vest through January 2027 and in six semi-annual installments beginning September 5, 2026, as well as shares acquired under the employee stock purchase plan.
Astrana Health, Inc. COO and CFO Basho Chandan reported a small tax-related share disposition. On April 2, 2026, he surrendered 2,092 shares of common stock at an assigned price of $25.05 per share to cover tax withholding obligations tied to restricted stock units that vested that day.
After this tax-withholding transaction, Chandan directly holds 171,635 shares of Astrana Health common stock. This figure includes unvested restricted stock and restricted stock units scheduled to vest over the next several years, subject to his continued employment with the company.
Astrana Health, Inc. filed an 8-K providing interim unaudited financial statements for PHP Holdings, LLC & Rhode Island Market and unaudited pro forma results reflecting Astrana’s acquisition of this business.
For the nine months ended June 30, 2025, the acquired business generated $961.8 million in net revenue, primarily from capitation of $830.4 million, but reported a net loss of $38.7 million. Total assets were $336.5 million and total liabilities $1.57 billion, including $1.26 billion of debt and $75.3 million of redeemable convertible preferred stock, resulting in a significant members’ deficit.
The notes explain PHP Holdings’ highly capitated model, major credit facilities such as the PhysicianCo Term Loan and Phase I Convertible Note, and confirm Astrana closed the acquisition of Alta Newport Hospital, Prospect Health Plan and related assets for $674.9 million on July 1, 2025.
Astrana Health, Inc. Chief Accounting Officer Glenn Sobotka reported a routine tax-withholding transaction involving company stock. On March 26, 2026, he surrendered 662 shares of common stock at $24.27 per share to cover taxes on restricted stock that vested that day. Following this non‑market disposition, he directly holds 14,039 shares, including unvested restricted stock awards. These include 4,824 shares scheduled to vest in three equal annual installments beginning on March 26, 2027, and 8,269 shares that will vest only if certain performance goals are achieved.
Astrana Health Inc disclosure: The Vanguard Group filed an amendment to its Schedule 13G reporting 0 shares of Common Stock and 0% ownership as of the amendment. The filing explains an internal realignment that led certain Vanguard subsidiaries to report beneficial ownership separately, and Vanguard disclaims beneficial ownership of those subsidiary-held shares.
Astrana Health, Inc. director Thomas S. Lam reported a tax-related share disposition. On March 5, 2026, he surrendered 9,266 shares of common stock at $25.07 per share to cover tax withholding on vested restricted stock, leaving 423,990 shares held directly.
He also reports indirect ownership of 6,132,802 shares of common stock through Allied Physicians of California, a Professional Medical Corporation, and 1,133,706 shares through the Thomas and Jeanette Lam 2002 Family Trust. He disclaims beneficial ownership of the Allied Physicians shares except to the extent of his pecuniary interest.
His direct holdings include restricted stock that may vest later, with 51,667 shares scheduled to vest in two equal annual installments beginning on March 5, 2027, and 26,667 shares vesting upon achievement of pre-established performance goals.
Astrana Health, Inc. Chief Medical Officer Dinesh M. Kumar reported a tax-withholding disposition of company stock. On March 5, 2026, 1,697 shares of common stock were surrendered at $25.07 per share to cover tax obligations related to vested restricted stock units.
After this withholding transaction, Kumar directly held 200,335 shares of Astrana Health common stock. This total includes time-based and performance-based restricted stock and restricted stock units that will vest over future dates, as well as 1,405 shares previously acquired under the employee stock purchase plan.
Astrana Health, Inc. COO and CFO Basho Chandan reported a tax-related share surrender. On March 5, 2026, he disposed of 1,240 shares of common stock at $25.07 per share to cover withholding taxes tied to vesting restricted stock units. After this tax-withholding disposition, he directly owned 173,727 shares, which the footnotes state include both vested shares and multiple tranches of unvested restricted stock and restricted stock units scheduled to vest over 2026 and 2027, subject to continued employment.
Astrana Health furnished an updated investor presentation outlining its value-based care model, recent growth, and financial outlook. For 2025, total revenue was $3.18 billion with $205.4 million of Adjusted EBITDA and $104.5 million of free cash flow. The company serves 1.6 million members in value-based arrangements through more than 20,000 providers across sixteen markets, and is shifting more business into full-risk capitation. For 2026, it guides to revenue of $3.8–$4.1 billion, Adjusted EBITDA of $250–$280 million, and free cash flow of $105–$132.5 million. Astrana also discusses an expected material weakness in internal control over financial reporting and its plan to file the 2025 Form 10-K by the Form 12b-25 extension deadline.